Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCLI Brainstorm Cell Therapeutics	$0.62 -3.9%	$0.95	$0.52 ▼ $5.67	$6.84M	0.12	618,944 shs	14,476 shs
GRTX Galera Therapeutics	$0.02 +1.8%	$0.03	$0.02 ▼ $0.08	$1.70M	1.91	91,196 shs	8,452 shs
MBIO Mustang Bio	$1.65 +0.3%	$1.70	$0.89 ▼ $21.95	$7.21M	2.22	2.57 million shs	64,042 shs
NLSP NLS Pharmaceutics	$2.71 -2.8%	$2.28	$1.30 ▼ $7.44	$9.75M	0.15	1.06 million shs	148,005 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCLI Brainstorm Cell Therapeutics	+4.03%	+0.78%	-24.56%	-45.34%	-88.73%
GRTX Galera Therapeutics	-8.30%	-5.15%	-12.30%	-9.05%	-70.92%
MBIO Mustang Bio	-2.96%	-3.53%	-24.77%	+37.82%	-91.48%
NLSP NLS Pharmaceutics	+8.14%	+30.99%	+25.68%	+62.21%	+1,473.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCLI Brainstorm Cell Therapeutics	2.5057 of 5 stars	0.0	5.0	0.0	4.7	2.5	0.8	0.6
GRTX Galera Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MBIO Mustang Bio	1.0231 of 5 stars	0.0	5.0	0.0	0.0	2.2	0.0	0.6
NLSP NLS Pharmaceutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCLI Brainstorm Cell Therapeutics	2.00	Hold	N/A	N/A
GRTX Galera Therapeutics	0.00	N/A	N/A	N/A
MBIO Mustang Bio	0.00	N/A	N/A	N/A
NLSP NLS Pharmaceutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest GRTX, BCLI, MBIO, and NLSP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/23/2025	BCLI Brainstorm Cell Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	($1.36) per share	N/A
GRTX Galera Therapeutics	N/A	N/A	N/A	N/A	($2.41) per share	N/A
MBIO Mustang Bio	N/A	N/A	N/A	N/A	$0.66 per share	N/A
NLSP NLS Pharmaceutics	N/A	N/A	N/A	N/A	($0.37) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCLI Brainstorm Cell Therapeutics	-$11.62M	-$3.10	N/A	N/A	N/A	N/A	N/A	-519.50%	N/A
GRTX Galera Therapeutics	-$59.08M	-$0.19	N/A	∞	N/A	N/A	N/A	-99.34%	N/A
MBIO Mustang Bio	-$15.75M	-$78.00	N/A	N/A	N/A	N/A	N/A	-29.49%	11/6/2025 (Estimated)
NLSP NLS Pharmaceutics	-$1.98M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest GRTX, BCLI, MBIO, and NLSP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/8/2025	Q2 2025	MBIO Mustang Bio	N/A	-$0.19	N/A	-$0.19	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	N/A
GRTX Galera Therapeutics	N/A	N/A	N/A	N/A	N/A
MBIO Mustang Bio	N/A	N/A	N/A	N/A	N/A
NLSP NLS Pharmaceutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCLI Brainstorm Cell Therapeutics	N/A	0.21	0.21
GRTX Galera Therapeutics	N/A	9.74	9.74
MBIO Mustang Bio	N/A	1.30	1.30
NLSP NLS Pharmaceutics	N/A	2.69	2.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCLI Brainstorm Cell Therapeutics	14.33%
GRTX Galera Therapeutics	50.77%
MBIO Mustang Bio	9.95%
NLSP NLS Pharmaceutics	N/A

Insider Ownership

Company	Insider Ownership
BCLI Brainstorm Cell Therapeutics	11.15%
GRTX Galera Therapeutics	12.90%
MBIO Mustang Bio	0.21%
NLSP NLS Pharmaceutics	16.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCLI Brainstorm Cell Therapeutics	40	11.04 million	8.74 million	Optionable
GRTX Galera Therapeutics	30	75.46 million	47.38 million	Optionable
MBIO Mustang Bio	100	4.38 million	4.37 million	Not Optionable
NLSP NLS Pharmaceutics	6	3.60 million	3.01 million	Not Optionable

GRTX, BCLI, MBIO, and NLSP Headlines

Recent News About These Companies

NLS Pharmaceutics Enters Warrant Exchange Agreement with Alpha Capital

August 14, 2025 | theglobeandmail.com

NLS Pharmaceutics (NASDAQ:NLSP) Upgraded at Wall Street Zen

August 12, 2025 | americanbankingnews.com

NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy

July 17, 2025 | prnewswire.com

NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing

June 30, 2025 | prnewswire.com

NLS Pharmaceutics Ltd.: NLS Pharmaceutics CEO Issues Letter to Shareholders

June 18, 2025 | finanznachrichten.de

NLS Pharmaceutics CEO Issues Letter to Shareholders

June 16, 2025 | prnewswire.com

NLS Pharmaceutics to present Mazindol study at ASCP Meeting

May 22, 2025 | investing.com

NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting

May 21, 2025 | prnewswire.com

NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models

April 15, 2025 | prnewswire.com

NLS Pharmaceutics, Kadimastem announce up to $3M equity financing

April 1, 2025 | markets.businessinsider.com

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement

March 31, 2025 | accessnewswire.comA

NLS Pharmaceutics CEO Issues Letter to Shareholders

March 10, 2025 | prnewswire.com

NLS Pharmaceutics announces new preclinical data for AEX-2

February 27, 2025 | markets.businessinsider.com

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

February 27, 2025 | prnewswire.com

NLS Pharmaceutics and Kadimastem complete pre-IND diabetes meeting with FDA

February 25, 2025 | markets.businessinsider.com

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

February 25, 2025 | prnewswire.com

NLS Pharmaceutics files $75M mixed securities shelf

February 11, 2025 | markets.businessinsider.com

NLS and Kadimastem to merge, aim for diabetes care innovation

February 10, 2025 | msn.com

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies

February 10, 2025 | prnewswire.com

NLS Pharmaceutics files to sell 645,161 common shares for holders

February 5, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRTX, BCLI, MBIO, and NLSP Company Descriptions

Brainstorm Cell Therapeutics NASDAQ:BCLI

$0.62 -0.03 (-3.88%)

As of 03:33 PM Eastern

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Galera Therapeutics NASDAQ:GRTX

$0.02 +0.00 (+1.81%)

As of 02:40 PM Eastern

Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

Mustang Bio NASDAQ:MBIO

$1.64 +0.01 (+0.30%)

Closing price 03:57 PM Eastern

Extended Trading

$1.68 +0.04 (+2.43%)

As of 04:10 PM Eastern

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

NLS Pharmaceutics NASDAQ:NLSP

$2.71 -0.08 (-2.83%)

Closing price 03:59 PM Eastern

Extended Trading

$2.69 -0.02 (-0.77%)

As of 04:04 PM Eastern

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time